Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue ...
Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated ...
4don MSN
Why some breast cancers evade treatment: Protein secreted by T cells may explain resistant tumors
Up to 20% of hormone receptor-positive breast cancers don't respond to antiestrogen therapies. A study led by researchers at ...
“By dividing and conquering…we’re seeing responses in multiple different subtypes of sarcoma…and moving toward more of an individualized therapy that we try to design for every patient, where we take ...
For San Diego researchers and the wider immunotherapy community, the atlas functions as a practical roadmap. It does not ...
Boston-based startup, Life Biosciences, is working on a treatment code-named ER-100 that involves reprogramming genes for ...
Please provide your email address to receive an email when new articles are posted on . Evidence of systemic mast cell activation in the PROSPECTOR study was split into three categories. A REMA score ...
Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, and variability in response, continue to impact therapeutic success.
According to the American Cancer Society, colorectal cancer is the second leading cause of cancer death. Enrichment of regulatory T cells (T-regs) in solid cancers is generally associated with poor ...
High numbers of regulatory T cells (red) — seen here interacting with antigen-presenting cells (blue) — are usually associated with poorer outcomes in cancer. A new MSK study, however, found that a ...
Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute myeloid leukaemia (r/r AML) and myelodysplastic syndrome (MDS ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results